These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 8019583)

  • 41. Connections between average and individual bioequivalence.
    Munk A
    Stat Med; 2000 Oct; 19(20):2843-54. PubMed ID: 11033579
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The subject-by-formulation interaction in multivariate bioequivalence.
    Cao L; Mathew T
    J Biopharm Stat; 2007; 17(3):367-79. PubMed ID: 17479387
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tolerance intervals for assessing individual bioequivalence.
    Brown EB; Iyer HK; Wang CM
    Stat Med; 1997 Apr; 16(7):803-20. PubMed ID: 9131767
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Measuring switchability and prescribability: when is average bioequivalence sufficient?
    Hauck WW; Anderson S
    J Pharmacokinet Biopharm; 1994 Dec; 22(6):551-64. PubMed ID: 7473081
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Investigation of the bioequivalence of two carbamazepine sustained-release formulations in healthy subjects.
    Schulz HU; Düsing R; Lührmann B; Frercks HJ
    Int J Clin Pharmacol Ther Toxicol; 1992 Oct; 30(10):410-4. PubMed ID: 1446959
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Statistical analysis of pharmacokinetic data with special applications to bioequivalence studies.
    Powers J; Powers T
    Ann Rech Vet; 1990; 21 Suppl 1():87S-92S. PubMed ID: 2080852
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bioequivalence review for drug interchangeability.
    Chow SC; Shao J
    J Biopharm Stat; 1999 Aug; 9(3):485-97. PubMed ID: 10473033
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Update on the statistical analysis of bioequivalence studies.
    Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S45-50. PubMed ID: 1601531
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessment of average, population and individual bioequivalence in two- and four-period crossover studies.
    Wijnand HP
    Comput Methods Programs Biomed; 2003 Jan; 70(1):21-35. PubMed ID: 12468124
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Individual bioequivalence: what matters to the patient.
    Hauck WW; Anderson S
    Stat Med; 1991 Jun; 10(6):959; discussion 959-60. PubMed ID: 1876785
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Residuals and outliers in replicate design crossover studies.
    Schall R; Endrenyi L; Ring A
    J Biopharm Stat; 2010 Jul; 20(4):835-49. PubMed ID: 20496209
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A small sample confidence interval approach to assess individual bioequivalence.
    Hyslop T; Hsuan F; Holder DJ
    Stat Med; 2000 Oct; 19(20):2885-97. PubMed ID: 11033583
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessing the agreement between two quantitative assays with repeated measurements.
    Shaoi J; Zhong B
    J Biopharm Stat; 2004 Feb; 14(1):201-12. PubMed ID: 15027509
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Robust and bootstrap testing procedures for bioequivalence.
    Shen CF; Iglewicz B
    J Biopharm Stat; 1994 Mar; 4(1):65-90. PubMed ID: 8019585
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of models for average bioequivalence in replicated crossover designs.
    Willavize SA; Morgenthien EA
    Pharm Stat; 2006; 5(3):201-11. PubMed ID: 17080753
    [TBL] [Abstract][Full Text] [Related]  

  • 56. On statistical power for average bioequivalence testing under replicated crossover designs.
    Wan H; Chow SC
    J Biopharm Stat; 2002 Aug; 12(3):295-309. PubMed ID: 12448572
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of the repeated cross-over designs in assessing bioequivalence.
    Liu JP
    Stat Med; 1995 May 15-30; 14(9-10):1067-78; discussion 1079-80. PubMed ID: 7569501
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Random-effects linear modeling and sample size tables for two special crossover designs of average bioequivalence studies: the four-period, two-sequence, two-formulation and six-period, three-sequence, three-formulation designs.
    Diaz FJ; Berg MJ; Krebill R; Welty T; Gidal BE; Alloway R; Privitera M
    Clin Pharmacokinet; 2013 Dec; 52(12):1033-43. PubMed ID: 24085600
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Experimental design and statistical methods for classical and bioequivalence hypothesis testing with an application to dairy nutrition studies.
    Tempelman RJ
    J Anim Sci; 2004; 82 E-Suppl():E162-172. PubMed ID: 15471796
    [TBL] [Abstract][Full Text] [Related]  

  • 60. On the statistical model of the two-stage designs in bioequivalence assessment.
    Karalis V; Macheras P
    J Pharm Pharmacol; 2014 Jan; 66(1):48-52. PubMed ID: 24175961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.